Ultragenyx to Present at 39th Annual J.P. Morgan Virtual Healthcare Conference

Rhea-AI Summary

Ultragenyx Pharmaceutical, a biopharmaceutical firm focused on rare genetic diseases, announced that CEO Emil D. Kakkis will present at the 39th Annual J.P. Morgan Virtual Healthcare Conference. The presentation is scheduled for January 12, 2021, at 2:50 PM EST. The live webcast will be accessible from their website, with a replay available for 30 days. Ultragenyx aims to develop novel therapies to address high unmet medical needs in rare diseases, guided by an experienced management team dedicated to efficient drug development.

NOVATO, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer and President, will present at the 39^th Annual J.P. Morgan Virtual Healthcare Conference on Tuesday, January 12, 2021 at 2:50 pm EST.

The live and archived webcast of the presentation will be accessible from the company’s website at http://ir.ultragenyx.com/events.cfm. The replay of the webcast will be available for 30 days.

About Ultragenyx

Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company’s website at www.ultragenyx.com.

Contact Ultragenyx Pharmaceutical Inc.
Investors & Media
Joshua Higa
415-660-0951

FAQ

When is Ultragenyx's presentation at the J.P. Morgan Virtual Healthcare Conference?

Ultragenyx's presentation is on January 12, 2021, at 2:50 PM EST.

Where can I watch the Ultragenyx presentation?

You can watch the presentation live on Ultragenyx's website, with a replay available for 30 days.

What is the focus of Ultragenyx Pharmaceutical?

Ultragenyx focuses on developing novel products for serious rare and ultra-rare genetic diseases.

Who is presenting for Ultragenyx at the conference?

Emil D. Kakkis, M.D., Ph.D., the CEO and President, will be presenting.

What type of diseases does Ultragenyx address?

Ultragenyx addresses diseases with high unmet medical need, particularly rare and ultra-rare genetic conditions.